WEDNESDAY, Dec. 5, 2018 (HealthDay News) — For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to a study published online Dec. 3 in The Lancet to coincide with the annual meeting of the American Society of Hematology, held from Dec. 1 to 4 in San Diego.
Steven Horwitz, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a double-blind, placebo-controlled, active-comparator phase 3 study involving 452 patients from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas. Patients were randomly assigned in a 1:1 ratio to receive either A+CHP or CHOP for six or eight 21-day cycles.
The researchers found a median progression-free survival of 48.2 and 20.8 months in the A+CHP and CHOP groups, respectively (hazard ratio, 0.71). Between the groups, adverse events were similar, including incidence and severity of febrile neutropenia (18 and 15 percent, respectively) and peripheral neuropathy (52 and 55 percent, respectively). Fatal adverse events occurred in 3 and 4 percent of patients, respectively.
“The addition of brentuximab vedotin to CHP resulted in higher rates of progression-free and overall survival without added toxicity and supports the potential for A+CHP to become a new standard of care for many patients with CD30-positive peripheral T-cell lymphoma,” the authors write.
Seattle Genetics, the manufacturer of brentuximab vedotin, and Millennium Pharmaceuticals partially funded the study.
Copyright © 2018 HealthDay. All rights reserved.